initial combination therapy may be required to achieve glycemic control. The American Association for Clinical Endocrinologists algorithm for the treatment of T2DM recommends metformin plus a sodium glucose co-transporter 2 (SGLT2) inhibitor as the first oral combination in patients who present with HbA1c C7.5%. Canagliflozin, an SGLT2 inhibitor, lowers the renal threshold for glucose and increases urinary glucose excretion leading to a mild osmotic diuresis and a net caloric loss. The effect of canagliflozin is insulin-independent and complementary to other AHAs, including metformin. A fixed-dose combination (FDC) of canagliflozin and metformin is also available with variable dosing, which may be attractive to some patients owing to the potential for reduced pill burden and costs. This article reviews the efficacy and safety of canagliflozin in combination with metformin based on data from the canagliflozin phase 3 clinical program.
As initial combination therapy in drug-naïve patients or as dual therapy with metformin or triple therapy in combination with metformin and other AHAs, canagliflozin 100 and 300 mg improved glycemic control and provided reductions in body weight and systolic blood pressure that were sustained for up to 104 weeks. Canagliflozin was generally well tolerated across studies in combination with metformin. An increased incidence of adverse events (AEs) related to the mechanism of SGLT2 inhibition (i.e., genital mycotic infections, urinary tract infections, osmotic 
INTRODUCTION
Clinical practice guidelines recommend metformin as a first-line pharmacologic therapy for the management of type 2 diabetes mellitus (T2DM) [1] [2] [3] . Metformin works by decreasing hepatic glucose production and intestinal glucose absorption and by improving insulin sensitivity, thereby enhancing peripheral glucose uptake [4, 5] . Enhanced excretion of glucagon-like peptide-1 with metformin may contribute to the intestinal glucose-lowering activity [6, 7] . Metformin may not be tolerated in all patients because of gastrointestinal side effects [8, 9] . Due to the progressive nature of T2DM, most patients eventually require combination therapy with other antihyperglycemic agents (AHAs) [2, 10, 11] . In addition, many patients can receive initial combination therapy at the time of diabetes diagnosis in order to reach glycemic goals efficiently. inhibitors are recommended by AACE as the first oral add-on for patients inadequately controlled on metformin [1] . Canagliflozin, an SGLT2 inhibitor, lowers plasma glucose levels in patients with T2DM by increasing urinary glucose excretion, resulting in a mild osmotic diuresis and a net caloric loss [13] . This insulin-independent mechanism of action is complementary to other types of AHAs, including metformin [2] . Across phase 3 trials, as monotherapy or in combination with metformin or other AHAs, canagliflozin 100 and 300 mg have been shown to provide not only glycemic improvement but also weight loss and blood pressure (BP) lowering in a broad range of patients with T2DM [14] . An oral fixed-dose combination (FDC) tablet of canagliflozin and metformin immediate release (IR) was approved in 2014 for the treatment of adults with T2DM [15] , and findings from a study of initial combination therapy with canagliflozin plus metformin extended release (XR) have recently been published [16] . This review summarizes the clinical data in support of the canagliflozin and metformin FDC. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
CANAGLIFLOZIN AND METFORMIN FDC
The canagliflozin and metformin IR FDC is indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2DM.
The canagliflozin and metformin IR FDC formulation is available in four dose strengths (50/500 mg, 50/1000 mg, 150/500 mg, 150/1000 mg) and should be taken twice daily with food [15] . Gradual dose escalation of metformin is recommended to limit gastrointestinal side effects associated with metformin.
The twice-daily dose of canagliflozin should not exceed 150 mg (total daily dose [TDD] of 300 mg), and canagliflozin should be restricted to 50 mg twice daily (TDD of 100 mg) for patients with estimated glomerular filtration rate (eGFR) C45 to \60 mL/min/1.73 m 2 [15] . An oral FDC containing immediate-release canagliflozin and metformin XR in a bilayer tablet formulation was recently approved in the USA [17] ; the XR FDC formulation was under development during the writing of this article and will be reviewed separately in a future publication. respectively; P = 0.001 for both comparisons; Table 2 ). Canagliflozin 100 and 300 mg monotherapy were noninferior in HbA1c lowering compared with metformin (-1.37%, -1.42%, and -1.30%, respectively). A greater proportion of patients achieved HbA1c \7.0%
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with both canagliflozin 100 mg/metformin and canagliflozin 300 mg/metformin than metformin alone at week 26 (49.6, 56.8, and 43.0%, respectively; P = 0.027 for canagliflozin 100 mg/metformin vs metformin and P = 0.016 for canagliflozin 300 mg/metformin vs metformin). Canagliflozin 100 mg/metformin and canagliflozin 300 mg/metformin provided greater body weight reductions compared with metformin alone (-3.5%, -4.2%, and -2.1%; P = 0.001 for both comparisons; Table 3 ).
Reductions in systolic BP were numerically greater with canagliflozin 100 mg/metformin and canagliflozin 300 mg/metformin compared with metformin alone (-2.2, -1.7, and -0.3 mmHg, respectively; Table 4 ).
Canagliflozin as Dual Therapy with Metformin
A 52-week study assessed the efficacy and safety of canagliflozin 100 and 300 mg versus placebo at week 26 and versus sitagliptin 100 mg as add-on to metformin [24] . Reductions in HbA1c
at week 26 were greater with canagliflozin 100 and 300 mg compared with placebo (-0.79%, -0.94%, and -0.17%, respectively; P\0.001 for both comparisons; Table 2 ). At week 52, canagliflozin 100 mg was noninferior and canagliflozin 300 mg was statistically superior to sitagliptin 100 mg in HbA1c lowering (-0.73%, -0.88%, and -0.73%, respectively; Table 2 ). A greater proportion of patients achieved HbA1c \7.0% with canagliflozin 100 and 300 mg compared to placebo at week 26 (46%, 58%, and 30%, respectively) and compared with sitagliptin 100 mg at week 52 (55%, 41%, and 51%, respectively). Canagliflozin 100 and 300 mg significantly reduced body weight compared with placebo (-3.7%, -4.2%, and -1.2%, respectively; P\0.001 for both comparisons; Table 3 ) at week 26. Greater reductions in body weight were seen with canagliflozin 100 and 300 mg versus sitagliptin 100 mg at week 52 (-3.8%, -4.2%, and -1.3%, respectively; P\0.001 for both comparisons; Table 3 ). At week 26, systolic BP reductions were seen with canagliflozin 100 and 300 mg (-3.8 and -5.1 mmHg, respectively) compared with an increase of 1.5 mmHg with placebo (P\0.001 for both comparisons; Table 4 ). At week 52, reductions in systolic BP were larger with canagliflozin 100 and 300 mg compared with sitagliptin 100 mg (-3.5, -4.7, and -0.7 mmHg, respectively; P\0.001 for both comparisons; Table 4 ).
A 104-week study assessed the efficacy and safety of canagliflozin 100 and 300 mg versus glimepiride as add-on to metformin at weeks 52 and 104 [25, 30] . At week 52, canagliflozin 100 mg demonstrated noninferiority and canagliflozin 300 mg demonstrated superiority in HbA1c lowering compared with glimepiride (-0.82%, -0.93%, and -0.81%, respectively; Table 2 ) [25] . Reductions in HbA1c were sustained at week 104 (-0.65%, -0.74%, and -0.55%, respectively; Table 2 ) [30] . At week 52, 54, 60, and 56% of patients achieved HbA1c \7.0% with canagliflozin 100 and 300 mg and glimepiride, respectively [25] . At week 104, 43, 50, and 44% of patients achieved HbA1c\7.0%, respectively [30] . Body weight at week 52 was significantly reduced with canagliflozin 100 and 300 mg (-4.2% and -4.7%, respectively), compared with a 1.0% increase with glimepiride (P\0.0001 for both comparisons; Table 3 ) [25] . Reductions in body weight with canagliflozin 100 and 300 mg versus glimepiride were maintained at week 104 (-4.1%, -4.2%, and 0.9%, respectively; Table 3 ) [30] . Reductions in systolic BP were seen with canagliflozin 100 and 300 mg (-3.3 and -4.6 mmHg) compared to an increase of 0.2 mmHg with glimepiride at 52 weeks (Table 4 ) [25] . At week 104, changes in systolic BP were -2.0, -3.1, and 1.7 mmHg, respectively (Table 4 ) [30] .
Canagliflozin in Combination with Metformin Plus Other AHAs
A 52-week study evaluated the efficacy and safety of canagliflozin 300 mg versus sitagliptin 100 mg as add-on to metformin plus sulfonylurea [28] . Canagliflozin 300 mg demonstrated superiority in HbA1c lowering versus sitagliptin 100 mg at week 52 (-1.03%
and -0.66%, respectively; Table 2 ). The greater HbA1c lowering with canagliflozin 300 mg was accompanied by a greater proportion of patients achieving HbA1c \7.0% with canagliflozin 300 mg versus sitagliptin 100 mg (48% vs 35%). Canagliflozin 300 mg significantly reduced body weight compared to sitagliptin 100 mg (-2.5% vs 0.3%; P\0.001; Table 3 ).
Canagliflozin 300 mg also significantly reduced systolic BP (-5.1 mmHg) versus an increase of 0.9 mmHg with sitagliptin 100 mg (P\0.001; Table 4 ).
A placebo-controlled study evaluated the efficacy and safety of canagliflozin 100 and 300 mg as add-on to metformin plus sulfonylurea at weeks 26 and 52 [27] . Canagliflozin 100 and 300 mg provided greater reductions in HbA1c compared with placebo at week 26 (-0.85%, -1.06%, and -0.13%, respectively; P\0.001 for both comparisons); these reductions were maintained at week 52 (-0.74%, -0.96%, and 0.01%, respectively; Table 2 ). A greater proportion of patients receiving canagliflozin 100 and 300 mg achieved HbA1c \7.0% at week 26 than those receiving placebo (43, 57, and 18%, respectively; P\0.001 for both comparisons).
At week 52, 39, 53, and 19% of patients achieved HbA1c \7.0% with canagliflozin 100
and 300 mg and placebo, respectively.
Significant body weight reductions were seen with canagliflozin 100 and 300 mg compared with placebo at week 26 (-2.1%, -2.6%, and -0.7%, respectively; P\0.001 for both comparisons) and were sustained at week 52 (-2.2%, -3.2%, and -0.9%, respectively; Table 3 ). Canagliflozin 100 and 300 mg provided numerically greater reductions in systolic BP compared with placebo at week 26 (-4.9, -4.3, and -2.7 mmHg, respectively); changes in systolic BP were -3.7, -2.9, and 0.1 mmHg, respectively, at week 52 (Table 4) .
In a study as add-on to metformin plus pioglitazone, the efficacy and safety of canagliflozin 100 and 300 mg were assessed versus placebo at week 26 [26] . The study included a 26-week extension during which patients receiving placebo were switched to sitagliptin 100 mg; this arm was not included in efficacy evaluations at week 52. At week 26, greater reductions in HbA1c were seen with canagliflozin 100 and 300 mg versus placebo (-0.89%, -1.03%, and -0.26%, respectively; P\0.001 for both comparisons; Table 2 ). A greater proportion of patients achieved HbA1c \7.0% with canagliflozin 100 and 300 mg versus placebo (47, 64, and 33%, respectively).
Reductions in body weight were greater with canagliflozin 100 and 300 mg compared with placebo at week 26 (-2.8%, -3.8%, and -0.1%, respectively; P\0.001 for both comparisons; Table 3 ). Similarly, canagliflozin 100 and 300 mg provided larger reductions in systolic BP compared with placebo (-5.3, -4.7, and -1.2 mmHg, respectively; Table 4 ). Reductions in HbA1c, body weight, and systolic BP with canagliflozin 100 and 300 mg were maintained at week 52 (Tables 2, 3, 4) .
In a prespecified analysis of a subset of patients with either a history or high risk of cardiovascular disease enrolled in the CANagliflozin cardioVascular Assessment Study (CANVAS) who were on background metformin plus insulin, the efficacy and safety of canagliflozin 100 and 300 mg were assessed versus placebo at week 18 [29] . Canagliflozin 100 and 300 mg reduced HbA1c compared with placebo (-0.64%, -0.79%, and 0.03%, respectively; P\0.001 for both comparisons; Table 2 ). A greater proportion of patients achieved HbA1c \7.0% with canagliflozin 100 and 300 mg versus placebo (19%, 29%, and 9%, respectively; P = 0.008 for canagliflozin 100 mg vs placebo; P\0.001 for canagliflozin 300 mg vs placebo). Significant reductions in body weight were seen with canagliflozin 100 and 300 mg compared with placebo (-1.7%, -2.7%, and 0.0%, respectively; P\0.001 for both comparisons; Table 3 ). Canagliflozin 100 and 300 mg provided larger reductions in systolic BP compared with placebo (-5.2, -7.7, and -1.7 mmHg, respectively; P\0.001 for canagliflozin 300 mg vs placebo; Table 4 ).
Safety and Tolerability
Canagliflozin in combination with metformin has been associated with a favorable safety and tolerability profile across phase 3 studies (Table 5 ) [16, [24] [25] [26] [27] [28] [29] [30] . Rates of AEs leading to discontinuation and serious AEs were generally low with canagliflozin versus comparators [16, [24] [25] [26] [27] [28] [29] [30] . Not surprisingly, the incidence of AEs related to SGLT2 inhibition (e.g., genital mycotic infections, urinary tract infections, osmotic diuresis-related AEs) was generally higher with canagliflozin versus comparators [16, [24] [25] [26] [27] [28] [29] [30] . Risk factors for genital mycotic infection include a prior history of recurrent genital mycotic infections and uncircumcision.
Older patients, those with reduced renal function, those with reduced BP, and those taking diuretics may be vulnerable to the volume depletion effects of canagliflozin. These patients, in particular, should be advised to drink plenty of non-sugar-containing fluids, and consideration should be given to reducing or holding their diuretics until after they are reassessed. Gastrointestinal intolerability is a common side effect of metformin [9] ; however, the combination of canagliflozin and metformin has not been associated with an increased incidence of gastrointestinal-related AEs (i.e., diarrhea, nausea, and vomiting) [31] .
Reports of hypoglycemia have been generally low with canagliflozin among patients not on background therapy associated with hypoglycemia (i.e., sulfonylurea or insulin) and in patients treated with initial canagliflozin/metformin combination therapy [16, [24] [25] [26] [27] [28] [29] [30] .
No serious AEs of diabetic ketoacidosis have been seen with canagliflozin as add-on to metformin alone or in combination with pioglitazone, or in the subset of patients from the CANVAS trial on background metformin plus insulin [32] . There was one serious ketoacidosis AE with canagliflozin 100 mg in the placebo-controlled add-on to metformin plus sulfonylurea study [27] , and the patient subsequently received a diagnosis of type 1 diabetes mellitus [32] . In the initial combination study [16] , there was one serious AE of ketoacidosis in a patient in the canagliflozin 300 mg group with confounding factors that included acute infection, chronic pancreatitis, and heart failure class II [32] . It is important to note that patients with HbA1c [10.5% were excluded from these studies. Overall safety and tolerability Generally well tolerated; low incidence of AEs leading to study discontinuation and serious AEs
Genital mycotic infections Higher incidence versus PBO, SITA, and GLIM; low incidence with CANA/MET in initial combination therapy
Generally mild or moderate in intensity; few led to study discontinuation Generally higher incidence in women than in men; more likely to occur in patients with a history of genital mycotic infections and in uncircumcised males UTIs Low incidence across studies; higher incidence versus GLIM and PBO; similar incidence compared with SITA Generally mild to moderate in intensity and few led to discontinuation; low incidence of serious or upper UTIs
Osmotic diuresis-related AEs (e.g., pollakiuria, polyuria, thirst)
Generally low incidence
Higher incidence versus PBO, SITA, and GLIM; few led to study discontinuation Volume depletion-related AEs (e.g., orthostatic hypotension, dizziness postural)
Generally low incidence; dose-dependent increase in incidence seen across studies
Incidence was higher in patients taking loop diuretics, in patients with moderate renal impairment (i.e., eGFR C30 to \60 mL/min/1.73 m 2 ), and in patients aged C75 years Gastrointestinal-related AEs (i.e., diarrhea, nausea, vomiting)
No increase in incidence with CANA as add-on to MET ± other AHAs versus PBO, SITA, or GLIM; incidence was low with CANA/MET as initial combination therapy Hypoglycemia Low incidence when not used in combination with background AHAs associated with hypoglycemia (e.g., SU or insulin)
Significantly lower incidence versus GLIM Slightly higher incidence with CANA as add-on to MET versus SITA; similar incidence with CANA as add-on to MET ? SU versus SITA with greater HbA1c lowering with CANA; incidence with CANA/ MET was similar to MET in initial combination therapy
Low incidence across studies of severe hypoglycemia episodes 
